Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Ofev

(NINTEDANIB)Orphan drugstandard

Boehringer Ingelheim Pharmaceuticals, Inc.

12.1 Mechanism of Action Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRT...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome.
Search all trials →
Search clinical trials for Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome

Recent News & Research

No recent news articles indexed yet for Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome.
Search PubMed for Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome

Browse all Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome news →

Specialist Network

No specialists currently listed for Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome.

View all Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome specialists →

Quick Actions